Valuation : OraSure Technologies, Inc.

Market Cap 224M 193M 183M 166M 311M 21.41B 313M 2.17B 835M 10.89B 842M 823M 34.43B P/E 2026 *
-4.92x
P/E 2027 * -4.01x
Enterprise Value 224M 193M 183M 166M 311M 21.41B 313M 2.17B 835M 10.89B 842M 823M 34.43B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.68x
Free-Float
93.64%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
1 week-6.61%
Current month-9.47%
1 month-16.24%
3 months-22.43%
6 months+2.20%
Current year+34.30%
1 week 3.14
Extreme 3.145
3.48
1 month 3.14
Extreme 3.145
4.05
Current year 2.33
Extreme 2.33
4.58
1 year 2.08
Extreme 2.08
4.58
3 years 2.08
Extreme 2.08
8.45
5 years 2.08
Extreme 2.08
13.57
10 years 2.08
Extreme 2.08
23.01
Manager TitleAgeSince
Chief Executive Officer 52 03/06/2022
Director of Finance/CFO 54 07/08/2022
Chief Tech/Sci/R&D Officer - 30/11/2024
Director TitleAgeSince
Director/Board Member 59 31/05/2020
Director/Board Member 66 07/11/2021
Director/Board Member 52 03/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
06/09/26 Tax

Chairman

-5,116 0.0074%
03/06/26 Free

Director

46,106 0.0670%
03/06/26 Free

Director

46,106 0.0670%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-6.61%-2.11%-46.01% 223M
-1.36%-5.89%-23.14%-0.49% 176B
-0.72%-3.41%-3.49%+11.74% 116B
+0.19%-2.83%+6.20%+80.93% 61.36B
-1.92%-6.01%+8.80%+41.11% 49.42B
+0.81%-3.73%-6.67%-33.43% 48.44B
-1.75%-5.54%+9.25%-22.61% 31.33B
+0.43%-11.10% - - 28.56B
+0.58%+1.84%+31.28%-12.82% 24.37B
+0.49%-7.65%-12.44%+4.86% 21.57B
Average -0.26%-5.23%+0.85%+2.59% 55.8B
Weighted average by Cap. -0.69%-4.90%-6.07%+10.83%

Financials

2026 *2027 *
Net sales 122M 105M 99.62M 90.29M 169M 11.67B 170M 1.18B 455M 5.93B 459M 449M 18.75B 133M 115M 109M 98.5M 185M 12.73B 186M 1.29B 496M 6.47B 500M 489M 20.46B
Net income -46.2M -39.8M -37.69M -34.16M -64.09M -4.41B -64.41M -448M -172M -2.25B -174M -170M -7.1B -57.65M -49.67M -47.04M -42.63M -79.98M -5.51B -80.39M -559M -215M -2.8B -217M -212M -8.85B
Net Debt - -
Logo OraSure Technologies, Inc.
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Employees
500
Date Price Change Volume
11/09/26 US$3.250 +0.62% 467,283
10/09/26 US$3.230 -3.87% 1,008,043
09/09/26 US$3.360 -0.88% 413,075
08/09/26 US$3.390 -2.59% 354,251
04/09/26 US$3.480 -2.79% 304,665
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.250USD
Average target price
4.000USD
Spread / Average Target
+23.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OSUR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!